Parkinson’s disease induced pluripotent stem cells with triplication of the α-synuclein locus
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
A major barrier to research on Parkinson's disease is inaccessibility of diseased tissue for study. One solution is to derive induced pluripotent stem cells from patients and differentiate them into neurons affected by disease. Triplication of SNCA, encoding α-synuclein, causes a fully penetrant, aggressive form of Parkinson's disease with dementia. α-Synuclein dysfunction is the critical pathogenic event in Parkinson's disease, multiple system atrophy and dementia with Lewy bodies. Here we produce multiple induced pluripotent stem cell lines from an SNCA triplication patient and an unaffected first-degree relative. When these cells are differentiated into midbrain dopaminergic neurons, those from the patient produce double the amount of α-synuclein protein as neurons from the unaffected relative, precisely recapitulating the cause of Parkinson's disease in these individuals. This model represents a new experimental system to identify compounds that reduce levels of α-synuclein, and to investigate the mechanistic basis of neurodegeneration caused by α-synuclein dysfunction. Pluripotent stem cells can be generated from the somatic cells of humans and are a useful model to study disease. Here, pluripotent stem cells are made from a patient with familial Parkinson's disease, and the resulting neurons exhibit elevated levels of α-synuclein, recapitulating the molecular features of the patient's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“SNCA triplication patient iPSC-derived dopaminergic neurons showed α-synuclein protein over accumulation which was consistent with pathological phenotype in PD patient [35].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Efficient Derivation of Functional Floor Plate Tissue from Human Embryonic Stem Cells
Fasano, C. A., Chambers, S. M., Lee, G., Tomishima, M. J., & Studer, L. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.03.001 · Cited by 209 · cited 1×
“The dual SMAD inhibition protocol has been employed to generate floor plate tissue from human ESC”
MethodRetractedSubramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673 · cited 1×
“A potential solution is to utilize reprogamming technology to generate disease-specific induced pluripotent stem cells (iPSCs”
BackgroundAnalyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190 · cited 1×
“Results were normalized to human TBP using the comparative C(T) metho”
MethodSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Self-citationHighly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009) · Nature Biotechnology · doi:10.1038/nbt.1529 · Cited by 3,620 · cited 1×
“Directed differentiation to dopaminergic neurons We used a feeder-free monolayer culture method of inducing neural differentiation under defined conditions, via dual inhibition of SMAD signallin”
MethodDisease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196 · cited 1×
“Generation of iPSCs from individuals with sporadic PD has been reporte”
BackgroundA Drosophila model of Parkinson's disease
Feany, M. B., & Bender, W. W. (2000) · Nature · doi:10.1038/35006074 · Cited by 2,118 · cited 1×
“Transgenic models of α-synuclein have illuminated pathogenic processes operating in P”
BackgroundDimos, J. T., Rodolfa, K. T., Niakan, K. K., Weisenthal, L. M., Mitsumoto, H., Chung, W., Croft, G. F., Saphier, G., Leibel, R., Goland, R., et al. (2008) · Science · doi:10.1126/science.1158799 · Cited by 1,962
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
Genome-wide association study reveals genetic risk underlying Parkinson's disease
Simón-Sánchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S. W., Hernandez, D. G., et al. (2009) · Nature Genetics · doi:10.1038/ng.487 · Cited by 1,751
Self-citationMaherali, N., Sridharan, R., Xie, W., Utikal, J., Eminli, S., Arnold, K., Stadtfeld, M., Yachechko, R., Tchieu, J., Jaenisch, R., et al. (2007) · Cell stem cell · doi:10.1016/j.stem.2007.05.014 · Cited by 1,725 · cited 1×
“Given the long latency and variability of disease progression, and that epigenetic modifications are erased during the process of generating iPSCs, it is unclear whether such patient-derived cells can recapitulate pathogenesis in cell cultur”
BackgroundSoldner, F., Hockemeyer, D., Beard, C., Gao, Q., Bell, G. W., Cook, E. G., Hargus, G., Blak, A., Cooper, O., Mitalipova, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.02.013 · Cited by 1,549 · cited 1×
“Generation of iPSCs from individuals with sporadic PD has been reporte”
BackgroundInduced pluripotent stem cells from a spinal muscular atrophy patient
Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N. (2009) · Nature · doi:10.1038/nature07677 · Cited by 1,441 · cited 1×
“This approach has already been used to generate cell models for several neurological conditions: amyotrophic lateral sclerosis, sporadic PD, spinal muscular atrophy and familial dysautonomia have all been describe”
MethodInduction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2
Huangfu, D., Osafune, K., Maehr, R., Guo, W., Eijkelenboom, A., Chen, S., Muhlestein, W., & Melton, D. A. (2008) · Nature Biotechnology · doi:10.1038/nbt.1502 · Cited by 1,341
Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.485 · Cited by 1,324
Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease
Ibáñez, P., Bonnet, A.-M., Débarges, B., Lohmann, E., Tison, F., Agid, Y., Dürr, A., Brice, A., & Pollak, P. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17104-3 · Cited by 1,044
Hu, B.-Y., Weick, J. P., Yu, J., Ma, L.-X., Zhang, X.-Q., Thomson, J. A., & Zhang, S.-C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910012107 · Cited by 1,013 · cited 1×
“This may reflect clonal variation or efficiency of neuralization that has been previously observed in iPSC”
ResultDerivation of midbrain dopamine neurons from human embryonic stem cells
Perrier, A. L., Tabar, V., Barberi, T., Rubio, M. E., Bruses, J., Topf, N., Harrison, N. L., & Studer, L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404700101 · Cited by 980
Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs
Lee, G., Papapetrou, E. P., Kim, H., Chambers, S. M., Tomishima, M. J., Fasano, C. A., Ganat, Y. M., Menon, J., Shimizu, F., Viale, A., et al. (2009) · Nature · doi:10.1038/nature08320 · Cited by 867 · cited 1×
“This approach has already been used to generate cell models for several neurological conditions: amyotrophic lateral sclerosis, sporadic PD, spinal muscular atrophy and familial dysautonomia have all been describe”
MethodGenetic Animal Models of Parkinson's Disease
Dawson, T. M., Ko, H. S., & Dawson, V. L. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.034 · Cited by 823 · cited 1×
“, but have not fully replicated the phenotype of the human diseas”
BackgroundIdentification and classification of chromosomal aberrations in human induced pluripotent stem cells
Mayshar, Y., Ben-David, U., Lavon, N., Biancotti, J.-C., Yakir, B., Clark, A. T., Plath, K., Lowry, W. E., & Benvenisty, N. (2010) · Cell stem cell · doi:10.1016/j.stem.2010.07.017 · Cited by 756 · cited 1×
“Chromosomal abnormalities of this nature are consistent with published reports of iPSCs where this has been specifically examine”
ResultLysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission
Alvarez-Erviti, L., Seow, Y., Schapira, A. H., Gardiner, C., Sargent, I. L., Wood, M. J. A., & Cooper, J. M. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.01.029 · Cited by 748 · cited 1×
“Finally, we asked whether AST-derived neurons might release more α-synuclein into cell culture media than NAS-derived neurons, as this protein is known to be secreted by cells in cultur”
BackgroundSelf-citationLRRK2 Mutant iPSC-Derived DA Neurons Demonstrate Increased Susceptibility to Oxidative Stress
Nguyen, H. N., Byers, B., Cord, B., Shcheglovitov, A., Byrne, J., Gujar, P., Kee, K., Schüle, B., Dolmetsch, R. E., Langston, W., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.01.013 · Cited by 745 · cited 1×
“More recently, an iPSC model of PD caused by homozygous G2019S mutation of LRRK2 has been reporte”
BackgroundPathoanatomy of Parkinson’s disease
Braak, H., & Braak, E. (2000) · Journal of Neurology · doi:10.1007/pl00007758 · Cited by 693
A functionally characterized test set of human induced pluripotent stem cells
Boulting, G. L., Kiskinis, E., Croft, G. F., Amoroso, M. W., Oakley, D. H., Wainger, B. J., Williams, D. J., Kahler, D. J., Yamaki, M., Davidow, L., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1783 · Cited by 489
Galvin, J. E., Uryu, K., Lee, V. M.-Y., & Trojanowski, J. Q. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13450 · Cited by 422 · cited 1×
“All have been found in neuritic pathology in PD and dementia with Lewy bodie”
BackgroundTechnical Challenges in Using Human Induced Pluripotent Stem Cells to Model Disease
Saha, K., & Jaenisch, R. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.11.009 · Cited by 411 · cited 1×
“Given the long latency and variability of disease progression, and that epigenetic modifications are erased during the process of generating iPSCs, it is unclear whether such patient-derived cells can recapitulate pathogenesis in cell cultur”
BackgroundRelationships between age and late progression of Parkinson's disease: a clinico-pathological study
Kempster, P. A., O'Sullivan, S. S., Holton, J. L., Revesz, T., & Lees, A. J. (2010) · Brain · doi:10.1093/brain/awq059 · Cited by 410 · cited 1×
“Moreover, by the time PD manifests clinically, most of these cells have already been los”
Backgroundβ-Synuclein Inhibits α-Synuclein Aggregation
Hashimoto, M., Rockenstein, E., Mante, M., Mallory, M., & Masliah, E. (2001) · Neuron · doi:10.1016/s0896-6273(01)00462-7 · Cited by 398
Feng, Q., Lu, S.-J., Klimanskaya, I., Gomes, I., Kim, D., Chung, Y., Honig, G. R., Kim, K.-S., & Lanza, R. (2010) · Stem Cells · doi:10.1002/stem.321 · Cited by 376 · cited 1×
“These sources of variation have also been observed in other iPSC model”
ResultMartinat, C., Shendelman, S., Jonason, A., Leete, T., Beal, M. F., Yang, L., Floss, T., & Abeliovich, A. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020327 · Cited by 364
α-Synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication
Miller, D. W., Hague, S. M., Clarimon, J., Baptista, M., Gwinn-Hardy, K., Cookson, M. R., & Singleton, A. B. (2004) · Neurology · doi:10.1212/01.wnl.0000127517.33208.f4 · Cited by 356
Self-citationGenomic investigation of α‐synuclein multiplication and parkinsonism
Ross, O. A., Braithwaite, A. T., Skipper, L. M., Kachergus, J., Hulihan, M. M., Middleton, F. A., Nishioka, K., Fuchs, J., Gasser, T., Maraganore, D. M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21380 · Cited by 342
Self-citationResearch in motion: the enigma of Parkinson's disease pathology spread
Brundin, P., Li, J.-Y., Holton, J. L., Lindvall, O., & Revesz, T. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2477 · Cited by 328
Multiple system atrophy: A primary oligodendrogliopathy
Wenning, G. K., Stefanova, N., Jellinger, K. A., Poewe, W., & Schlossmacher, M. G. (2008) · Annals of Neurology · doi:10.1002/ana.21465 · Cited by 324
Genetic Analysis of Pathways to Parkinson Disease
Hardy, J. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.014 · Cited by 274 · cited 1×
“It is unclear why neurons degenerate in PD, but clues have been provided through studying the underlying genetics of the disorde”
BackgroundSelf-citationα-Synuclein gene duplication is present in sporadic Parkinson disease
Ahn, T. B., Kim, S. Y., Kim, J. Y., Park, S. S., Lee, D. S., Min, H. J., Kim, Y. K., Kim, S. E., Kim, J. M., Kim, H. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000271080.53272.c7 · Cited by 249
The UK Parkinson's Disease Consortium and The Wellcome Trust Case Control Consortium 2, Spencer, C. C. A., Plagnol, V., Strange, A., Gardner, M., Paisan-Ruiz, C., Band, G., Barker, R. A., Bellenguez, C., Bhatia, K., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq469 · Cited by 219
Self-citationKim, D.-S., Lee, J. S., Leem, J. W., Huh, Y. J., Kim, J. Y., Kim, H.-S., Park, I.-H., Daley, G. Q., Hwang, D.-Y., & Kim, D.-W. (2010) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9138-1 · Cited by 209 · cited 1×
“Here we have also added Dorsomorphin (a chemical BMP inhibitor) as a partial substitute for Noggin, to improve efficiency and reduce cost”
BackgroundHereditary form of parkinsonism—dementia
Muenter, M. D., Forno, L. S., Hornykiewicz, O., Kish, S. J., Maraganore, D. M., Caselli, R. J., Okazaki, H., Howard, F. M., Snow, B. J., & Calne, D. B. (1998) · Annals of Neurology · doi:10.1002/ana.410430612 · Cited by 201 · cited 1×
“Results PD fibroblasts do not express α-synuclein Muenter and co-workers reported the original description of the Iowan kindred, with a long family history of early-onset Parkinsonism and dementi”
BackgroundGwinn-Hardy, K., Mehta, N. D., Farrer, M., Maraganore, D., Muenter, M., Yen, S. H., Hardy, J., & Dickson, D. W. (2000) · Acta Neuropathologica · doi:10.1007/s004010051177 · Cited by 184
Self-citationCell systems and the toxic mechanism(s) of α-synuclein
Cookson, M. R., & van der Brug, M. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2007.05.022 · Cited by 173 · cited 1×
“This is important, because determining these earliest responses might provide a mechanism whereby the disease can be halted before it progresses, and, furthermore, those pathological changes that occur at later stages in the disease may be protective rather than toxi”
BackgroundHotta, A., & Ellis, J. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21912 · Cited by 173
Constructing and Deconstructing Stem Cell Models of Neurological Disease
Han, S. S. W., Williams, L. A., & Eggan, K. C. (2011) · Neuron · doi:10.1016/j.neuron.2011.05.003 · Cited by 159 · cited 1×
“Therefore it is an implicit requirement to generate several independent iPSC lines from each patient involved in a study of this nature, and to examine efficiency of neuralization for fair comparisons to be mad”
BackgroundGene dosage and pathogenesis of Parkinson's disease
Eriksen, J. L., Przedborski, S., & Petrucelli, L. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.01.001 · Cited by 122 · cited 1×
“Many of the existing cellular models rely on poorly controlled overexpression of transgenes, a particular drawback when modelling a disease where subtle alteration of gene dosage is critica”
Backgroundγ-Synucleinopathy: neurodegeneration associated with overexpression of the mouse protein
Ninkina, N. N., Peters, O. M., Millership, S. J., Salem, H., van der Putten, H., & Buchman, V. L. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp090 · Cited by 119
Ishihara, L., Gibson, R. A., Warren, L., Amouri, R., Lyons, K., Wielinski, C., Hunter, C., Swartz, J. E., Elango, R., Akkari, P. A., et al. (2007) · Movement Disorders · doi:10.1002/mds.21180 · Cited by 93 · cited 1×
“However, LRRK2 mutations have incomplete penetrance, even when homozygou”
BackgroundA β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain
Fujita, M., Sugama, S., Sekiyama, K., Sekigawa, A., Tsukui, T., Nakai, M., Waragai, M., Takenouchi, T., Takamatsu, Y., Wei, J., et al. (2010) · Nature Communications · doi:10.1038/ncomms1101 · Cited by 78
Limitations of cellular models in Parkinson’s disease research
Falkenburger, B. H., & Schulz, J. B. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_40 · Cited by 71
ENZYMATIC AND CHROMOSOMAL CHARACTERIZATION OF HELA VARIANTS
Bottomley, R. H., Trainer, A. L., & Griffin, M. J. (1969) · The Journal of Cell Biology · doi:10.1083/jcb.41.3.806 · Cited by 71 · cited 1×
“Transformed cell lines can be genetically manipulated for studying proteins of interest, but these cells carry mutations in genes involved in apoptosis and chromosomal rearrangements that can disrupt cell signalling pathways, and are phenotypically different from the cells affected by PD, all of which limits their use…”
BackgroundPostnatal ontogeny of the transcription factor Lmx1b in the mouse central nervous system
Dai, J., Hu, Z., Shi, M., Guo, C., & Ding, Y. (2008) · Journal of Comparative Neurology · doi:10.1002/cne.21759 · Cited by 62
Expression and Subcellular Location of Alpha-Synuclein During Mouse-Embryonic Development
Zhong, S., Luo, X. G., Chen, X.-S., Cai, Q., Liu, J., Chen, X., & Yao, Z. (2009) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-009-9473-4 · Cited by 61 · cited 1×
“We observed considerable heterogeneity of expression of α-synuclein that may reflect different neuronal subtypes or different stages of neuronal maturit”
BackgroundClinical features and diagnosis.
Migasena, S., Gilles, H. M., & Ball, P. A. J. (1991) · Cited by 53
Gwinn, K. A., Devine, M. J., Jin, L., Johnson, J. O., Bird, T. D., Muenter, M. D., Waters, C., Adler, C. H., Caselli, R. J., Houlden, H., et al. (2011) · Movement Disorders · doi:10.1002/mds.23776 · Cited by 40
Self-citationDolan, C. V., Boomsma, D. I., & Neale, M. C. (1999) · The American Journal of Human Genetics · doi:10.1086/302189 · Cited by 23 · cited 1×
“This SNP data also confirmed that AST and NAS iPSCs and neurons were indeed derived from the PD patient and unaffected relative, respectively ( Table 1”
ResultThreonine 53 in α-synuclein is conserved in long-living non-primate animals
Larsen, K., Hedegaard, C., Bertelsen, M. F., & Bendixen, C. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.07.070 · Cited by 17
Cited by
Induced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525
Genetics of Parkinson's Disease
Klein, C., & Westenberger, A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a008888 · Cited by 1,358
Goedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.242 · Cited by 1,190
Shi, Y., Kirwan, P., & Livesey, F. J. (2012) · Nature Protocols · doi:10.1038/nprot.2012.116 · Cited by 972
Induced Pluripotent Stem Cells: Past, Present, and Future
Yamanaka, S. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.005 · Cited by 843
“…iPSCs can be used to recapitulate phenotypes of not only monogenic diseases but also late-onset polygenic diseases, such as Parkinson’s disease (Devine et al., 2011), Alzheimer’s disease (Israel et al., 2012; Yagi et al., 2011; Yahata et al., 2011), and schizophrenia (Brennand et al., 2011).”
Metadata
- Authors
- Devine, M. J., Ryten, M., Vodicka, P., Thomson, A. J., Burdon, T., Houlden, H., Cavaleri, F., Nagano, M., Drummond, N. J., Taanman, J.-W., Schapira, A. H., Gwinn, K., Hardy, J., Lewis, P. A., & Kunath, T.
- Affiliations
- MRC Centre for Regenerative Medicine (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- Roslin Institute (GB)
- University of Tsukuba (JP)
- Baylor College of Medicine (US)
- Corresponding author
- Devine, Michael J.
- Kunath, Tilo
- ORCID
- Venue
- Nature Communications
- Published
- 2011-08-23
- Volume
- 2
- Issue
- 1
- Pages
- 440-440
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3265381
- OpenAlex
- W1985010554
- Cited by
- 486
- References
- 61
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 27 · 2023: 25 · 2022: 40 · 2021: 26 · 2020: 43 · 2019: 24 · 2018: 46 · 2017: 34 · 2016: 34 · 2015: 38 · 2014: 29 · 2013: 32 · 2012: 48
- FWCI
- 22.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature Communications (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- ASEP (submittedVersion, public-domain)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Michael J. Fox Foundation for Parkinson's Research
- University of Dundee
- Wellcome Trust (089698)
- Parkinson's UK (K-0911, G-4046, G-0907, F1002), F-0902)
- Brain Research Trust
- University of Sheffield
- Medical Research Council (MC_G1000735)
- Biotechnology and Biological Sciences Research Council (BBS/E/R/00001627, BBS/E/R/00001601)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, induced pluripotent stem cells, alpha-synuclein, SNCA triplication, familial Parkinson's disease, midbrain dopaminergic neurons, disease modeling, neurodegeneration, multiple system atrophy, dementia with Lewy bodies, alpha-synuclein overexpression
- MeSH terms
- Cell Differentiation, Cells, Cultured, Humans, Neurons, Parkinson Disease, Gene Dosage, alpha-Synuclein, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.